Therapeutics for treating mpox in humans

Tilly Fox; Susie Gould; Naveena Princy; Tim Rowland; Vittoria Lutje; Rebecca Kuehn

doi:10.1002/14651858.cd015769

Therapeutics for treating mpox in humans

Tilly Fox, Susie Gould, Naveena Princy, Tim Rowland, Vittoria Lutje, Rebecca Kuehn

Research output: Contribution to journal › Review article › peer-review

36 Citations (Scopus)

Abstract

Mpox was declared a Public Health Emergency of International Concern (PHEIC) by the World Health Organization (WHO) on 23 July 2022, following the identification of thousands of cases in several non‐endemic countries in previous months. There are currently no licenced therapeutics for treating mpox; however, some medications may be authorized for use in an outbreak. The efficacy and safety of possible therapeutic options has not been studied in humans with mpox. There is a need to investigate the evidence on safety and effectiveness of treatments for mpox in humans; should any therapeutic option be efficacious and safe, it may be approved for use around the world.

Original language	English
Article number	CD015769
Pages (from-to)	CD015769
Journal	Cochrane Database of Systematic Reviews
Volume	2023
Issue number	3
DOIs	https://doi.org/10.1002/14651858.cd015769
Publication status	Published - 14 Mar 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/14651858.cd015769

Fox et al-2023-Cochrane Database of Systematic Reviews (2)Final published version, 720 KB

Cite this

@article{f9bf4af80622400f89e1b284c0034238,

title = "Therapeutics for treating mpox in humans",

abstract = "Mpox was declared a Public Health Emergency of International Concern (PHEIC) by the World Health Organization (WHO) on 23 July 2022, following the identification of thousands of cases in several non‐endemic countries in previous months. There are currently no licenced therapeutics for treating mpox; however, some medications may be authorized for use in an outbreak. The efficacy and safety of possible therapeutic options has not been studied in humans with mpox. There is a need to investigate the evidence on safety and effectiveness of treatments for mpox in humans; should any therapeutic option be efficacious and safe, it may be approved for use around the world.",

author = "Tilly Fox and Susie Gould and Naveena Princy and Tim Rowland and Vittoria Lutje and Rebecca Kuehn",

year = "2023",

month = mar,

day = "14",

doi = "10.1002/14651858.cd015769",

language = "English",

volume = "2023",

pages = "CD015769",

journal = "Cochrane Database of Systematic Reviews",

issn = "1465-1858",

publisher = "John Wiley and Sons Ltd",

number = "3",

}

TY - JOUR

T1 - Therapeutics for treating mpox in humans

AU - Fox, Tilly

AU - Gould, Susie

AU - Princy, Naveena

AU - Rowland, Tim

AU - Lutje, Vittoria

AU - Kuehn, Rebecca

PY - 2023/3/14

Y1 - 2023/3/14

N2 - Mpox was declared a Public Health Emergency of International Concern (PHEIC) by the World Health Organization (WHO) on 23 July 2022, following the identification of thousands of cases in several non‐endemic countries in previous months. There are currently no licenced therapeutics for treating mpox; however, some medications may be authorized for use in an outbreak. The efficacy and safety of possible therapeutic options has not been studied in humans with mpox. There is a need to investigate the evidence on safety and effectiveness of treatments for mpox in humans; should any therapeutic option be efficacious and safe, it may be approved for use around the world.

AB - Mpox was declared a Public Health Emergency of International Concern (PHEIC) by the World Health Organization (WHO) on 23 July 2022, following the identification of thousands of cases in several non‐endemic countries in previous months. There are currently no licenced therapeutics for treating mpox; however, some medications may be authorized for use in an outbreak. The efficacy and safety of possible therapeutic options has not been studied in humans with mpox. There is a need to investigate the evidence on safety and effectiveness of treatments for mpox in humans; should any therapeutic option be efficacious and safe, it may be approved for use around the world.

U2 - 10.1002/14651858.cd015769

DO - 10.1002/14651858.cd015769

M3 - Review article

SN - 1465-1858

VL - 2023

SP - CD015769

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 3

M1 - CD015769

ER -